Self-Organization of Pristine C60 Fullerene and its Complexes with Chemotherapy Drugs in Aqueous Solution as Promising Anticancer Agents

Author(s):  
Leonid A. Bulavin ◽  
Yuriy Prylutskyy ◽  
Olena Kyzyma ◽  
Maxim Evstigneev ◽  
Uwe Ritter ◽  
...  
Author(s):  
Justyna Łuczak ◽  
Jan Hupka ◽  
Jorg Thöming ◽  
Christian Jungnickel

2021 ◽  
pp. 107815522110562
Author(s):  
Moataz M Hassan ◽  
Dhabya Al-Marzooq ◽  
Hanan Al-Habsi ◽  
Amna Al-Hashar ◽  
Murtadha Al-Khabori ◽  
...  

Background Safe handling of oral anticancer agents is of great concern. There is a lack of clear, national guidelines on how patients can safely handle and dispose of unwanted medications. We aimed to evaluate the safe handling, storage, and disposal of oral anticancer drugs among cancer patients and caregivers at home. Method This cross-sectional survey of adult cancer patients (or their adult caregivers) used a closed-ended questionnaire from May 2019 to March 2020. Results A total of 257 patients (50 ± 15 years; range: 18–93 years) were enrolled; however, only 91% (233/257) reported self-administering oral anticancer medications. Caregivers were more likely to administer oral anticancer agents for patients ≥60 years than those <40 years old (63% vs. 8%; P = 0.001). Most patients (52%; 133/257) did not wash their hands after administering the drug; 74% (164/222) of the respondents reported that their medications were kept in a bedroom cabinet, while 18% (40/222) stored their medications in a refrigerator, and 5% (12/222) in a kitchen cabinet. A total of 55% (68/124) of patients returned their excess oral chemotherapy medications to the hospitals; however, 36% (45/124) disposed of their unused oral chemotherapy drugs in a household garbage container. Conclusion While two-thirds of patients stored their oral anticancer medications properly, more than half used inappropriate handling procedures. Disposal practices were inconsistent and did not adhere to the reported international guidelines.


Molecules ◽  
2019 ◽  
Vol 24 (3) ◽  
pp. 471 ◽  
Author(s):  
Anna Corrêa ◽  
Mauricio Vericimo ◽  
Andriy Dashevskiy ◽  
Patricia Pereira ◽  
Vania Paschoalin

The search for natural anticancer agents and nanocarrier uses are a part of the current strategies to overcome the side effects caused by chemotherapeutics. Liposomal nanocapsules loaded with purified tarin, a potential immunomodulatory and antitumoral lectin found in taro corms, were produced. Liposomes were composed by 1,2-dioleoyl-sn-glycerol-3-phosphoethanolamine, cholesterylhemisuccinate, and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[folate(polyethylene glycol)-2000 prepared by thin-film hydration. Small unilamellar vesicles were achieved by sonication and extrusion. Scanning electron microscopy evidenced round-shaped nanocapsules presenting a smooth surface, 150 nm diameter and polydispersity index <0.2, estimated by dynamic light scattering. Tarin entrapment rates were over 80% and leakage of ~3% under 40 days of storage at 4 °C. Entrapped tarin exhibited an 83% release after 6 h at pH 4.6–7.4 and 36 °C. Both free and encapsulated tarin exhibited no in vitro toxicity against healthy mice bone marrow and L929 cells but stimulated the production of fibroblast-like and large round-shaped cells. Encapsulated tarin resulted in inhibition of human glioblastoma (U-87 MG) and breast adenocarcinoma (MDA-MB-231) proliferation, with an IC50 of 39.36 and 71.38 µg/mL, respectively. The effectiveness of encapsulated tarin was similar to conventional chemotherapy drugs, such as cisplatin and temozolide. Tarin liposomal nanocapsules exhibited superior pharmacological activity compared to free tarin as a potential chemotherapy adjuvant.


2019 ◽  
Vol 721 ◽  
pp. 22-26 ◽  
Author(s):  
Andrei Mosunov ◽  
Vladyslav Evstigneev ◽  
Anatoly Buchelnikov ◽  
Viktoria Salo ◽  
Yuriy Prylutskyy ◽  
...  

2019 ◽  
Vol 61 (1) ◽  
pp. 96-104 ◽  
Author(s):  
D. V. Vishnevetskii ◽  
A. N. Adamyan ◽  
V. S. Laguseva ◽  
A. I. Ivanova ◽  
S. D. Khizhnyak ◽  
...  

Molecules ◽  
2020 ◽  
Vol 25 (10) ◽  
pp. 2436 ◽  
Author(s):  
Petra Grbčić ◽  
Mirela Sedić

Colorectal carcinoma (CRC) is the leading cause of cancer-related deaths worldwide. Despite advances in prevention and treatment modalities for CRC, rapidly developing resistance to chemotherapy limits its effectiveness. For that reason, it is important to better understand the mechanisms that undergird the process of chemoresistance to enable design of novel anticancer agents specifically targeting malignant properties of cancer cells. Over recent decades, bioactive sphingolipid species have come under the spotlight for their recognized role in cancer development and progression, and the evidence has surfaced to support their role as regulators of anti-cancer drug resistance. Colon cancer is characterized by a shift in sphingolipid balance that favors the production and accumulation of oncogenic species such as sphingosine 1-phosphate (S1P). S1P is known to govern the processes that facilitate cancer cell growth and progression including proliferation, survival, migration, invasion and inflammation. In this review paper, we will give a comprehensive overview of current literature findings on the molecular mechanisms by which S1P turnover, transport and signaling via receptor-dependent and independent pathways shape colon cancer cell behavior and influence treatment outcome in colon cancer. Combining available modulators of S1P metabolism and signaling with standard chemotherapy drugs could provide a rational approach to achieve enhanced therapeutic response, diminish chemoresistance development and improve the survival outcome in CRC patients.


2014 ◽  
Vol 140 (10) ◽  
pp. 104909 ◽  
Author(s):  
Dmitry P. Voronin ◽  
Anatoly S. Buchelnikov ◽  
Viktor V. Kostjukov ◽  
Sergii V. Khrapatiy ◽  
Dariusz Wyrzykowski ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document